These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17982480)

  • 1. Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.
    Jopling LA; Watt GF; Fisher S; Birch H; Coggon S; Christie MI
    Br J Pharmacol; 2007 Dec; 152(8):1260-71. PubMed ID: 17982480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with Gi-protein pathway activation.
    Watts AO; Scholten DJ; Heitman LH; Vischer HF; Leurs R
    Biochem Biophys Res Commun; 2012 Mar; 419(2):412-8. PubMed ID: 22349504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological blockade of CXCR3 by (±)-NBI-74330 reduces neuropathic pain and enhances opioid effectiveness - Evidence from in vivo and in vitro studies.
    Piotrowska A; Rojewska E; Pawlik K; Kreiner G; Ciechanowska A; Makuch W; Zychowska M; Mika J
    Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3418-3437. PubMed ID: 30076959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
    Heise CE; Pahuja A; Hudson SC; Mistry MS; Putnam AL; Gross MM; Gottlieb PA; Wade WS; Kiankarimi M; Schwarz D; Crowe P; Zlotnik A; Alleva DG
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1263-71. PubMed ID: 15761110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes.
    Korniejewska A; McKnight AJ; Johnson Z; Watson ML; Ward SG
    Immunology; 2011 Apr; 132(4):503-15. PubMed ID: 21255008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3.
    Scholten DJ; Canals M; Wijtmans M; de Munnik S; Nguyen P; Verzijl D; de Esch IJ; Vischer HF; Smit MJ; Leurs R
    Br J Pharmacol; 2012 Jun; 166(3):898-911. PubMed ID: 21883151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CXCL10 receptor antagonist on islet cell apoptosis in a type I diabetes rat model.
    He J; Lian C; Fang Y; Wu J; Weng J; Ye X; Zhou H
    Int J Clin Exp Pathol; 2015; 8(11):14542-8. PubMed ID: 26823775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3.
    Nedjai B; Li H; Stroke IL; Wise EL; Webb ML; Merritt JR; Henderson I; Klon AE; Cole AG; Horuk R; Vaidehi N; Pease JE
    Br J Pharmacol; 2012 Jun; 166(3):912-23. PubMed ID: 21895630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of overlapping but differential binding sites for the high-affinity CXCR3 antagonists NBI-74330 and VUF11211.
    Scholten DJ; Roumen L; Wijtmans M; Verkade-Vreeker MC; Custers H; Lai M; de Hooge D; Canals M; de Esch IJ; Smit MJ; de Graaf C; Leurs R
    Mol Pharmacol; 2014 Jan; 85(1):116-26. PubMed ID: 24174496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
    Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M
    J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice.
    van Wanrooij EJ; de Jager SC; van Es T; de Vos P; Birch HL; Owen DA; Watson RJ; Biessen EA; Chapman GA; van Berkel TJ; Kuiper J
    Arterioscler Thromb Vasc Biol; 2008 Feb; 28(2):251-7. PubMed ID: 18048768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.
    Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G
    Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors.
    Verzijl D; Storelli S; Scholten DJ; Bosch L; Reinhart TA; Streblow DN; Tensen CP; Fitzsimons CP; Zaman GJ; Pease JE; de Esch IJ; Smit MJ; Leurs R
    J Pharmacol Exp Ther; 2008 May; 325(2):544-55. PubMed ID: 18270317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11).
    Sauty A; Colvin RA; Wagner L; Rochat S; Spertini F; Luster AD
    J Immunol; 2001 Dec; 167(12):7084-93. PubMed ID: 11739530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.
    Colvin RA; Campanella GS; Sun J; Luster AD
    J Biol Chem; 2004 Jul; 279(29):30219-27. PubMed ID: 15150261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Effects of Chemokine Receptors CXCR2 and CXCR3 Pharmacological Modulation in Neuropathic Pain Model-
    Piotrowska A; Ciapała K; Pawlik K; Kwiatkowski K; Rojewska E; Mika J
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
    Karin N
    Front Immunol; 2020; 11():976. PubMed ID: 32547545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational Study of C-X-C Chemokine Receptor (CXCR)3 Binding with Its Natural Agonists Chemokine (C-X-C Motif) Ligand (CXCL)9, 10 and 11 and with Synthetic Antagonists: Insights of Receptor Activation towards Drug Design for Vitiligo.
    Aguilera-Durán G; Romo-Mancillas A
    Molecules; 2020 Sep; 25(19):. PubMed ID: 32992956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding.
    Cox JH; Dean RA; Roberts CR; Overall CM
    J Biol Chem; 2008 Jul; 283(28):19389-99. PubMed ID: 18411283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemokine receptor CXCR3 promotes growth of glioma.
    Liu C; Luo D; Reynolds BA; Meher G; Katritzky AR; Lu B; Gerard CJ; Bhadha CP; Harrison JK
    Carcinogenesis; 2011 Feb; 32(2):129-37. PubMed ID: 21051441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.